Aphase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosi
Pathology and candidate patients
Dr. Luís Martí Bonmatí
Hospital Quirónsalud Valencia.
Active. Start date 2013
April 18, 2013
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the image diagnosis team by sending an email to the address: firstname.lastname@example.org